Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab Combinations in Relapsed/Refractory Multiple Myeloma
NCT04892446Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Nov 2021
- Primary completion
- Apr 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of magrolimab in multiple myeloma (MM), sponsored by Gilead Sciences. Started Nov 2021; status: terminated.
02
Drugs
magrolimab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04892446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04892446.